Nanolipidic particle assembly populations
Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.
1. An NLP (Nanolipidic Particle) assembly population comprising:
nanolipidic particles (NLPs), said nanolipidic particles formed from a hydrous monophasic precursor solution having phospholipids, a first concentration of aqueous solvent and a first concentration of non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol;
said hydrous monophasic precursor solution having been diluted by one or more dilution of a second concentration non-aqueous solvent resulting in a solvent-diluted precursor; and
said solvent-diluted precursor having been diluted with a second concentration of aqueous solvent;
wherein the dilution with said second concentration of aqueous solvent results in formation of one or more NLP assembly having a mean size from about 30 nm to about 200 nm, said nanolipidic particles in said assembly having a mean size of about 1 nm to about 20 nm and retaining a concentration of said non-aqueous solvent from about 0.5% to 14%.
2. The NLP assembly population of claim 1 , wherein the mean size of said assembly is from about 80 nm to about 110 nm.
3. The NLP assembly population of claim 1 , wherein the mean size of said assembly is from about 110 nm to about 140 nm.
4. The NLP assembly population of claim 1 , wherein the mean size of said assembly is from about 150 nm to about 200 nm.
5. The NLP assembly population of claim 1 , wherein said non-aqueous solvent is ethanol.
6. The NLP assembly population of claim 1 , wherein said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
7. The NLP assembly population of claim 1 , wherein said non-aqueous solvent is ethanol and said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
8. The NLP assembly population of claim 1 , wherein said NLP assembly populations are for oral consumption.
9. The NLP assembly population of claim 7 , wherein said NLP assembly populations are for oral consumption.
10. The NLP assembly population of claim 1 , wherein said NLP assembly populations are for topical application.
11. The NLP assembly population of claim 7 , wherein said NLP assembly populations are for topical application.
12. The NLP assembly population of claim 1 , wherein a passenger molecule is encapsulated within said nanolipidic particles prior to forming said NLP assembly population.
13. The NLP assembly population of claim 7 , wherein a passenger molecule is encapsulated within said nanolipidic particles prior to forming said NLP assembly population.
14. An NLP (Nanolipidic Particle) assembly population comprising:
one or more passenger-loaded nanolipidic particle (NLP), said nanolipidic particles formed from a hydrous monophasic precursor solution having phospholipids, water and a non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol;
said hydrous monophasic precursor solution having been diluted by one or more dilution of non-aqueous solvent resulting in a solvent-diluted precursor; and
said solvent-diluted precursor having been diluted with an aqueous solution;
wherein the dilution of said nanolipidic particles with said aqueous solution results in formation of one or more NLP assembly having a mean assembly size in said population from about 30 nm to about 200 nm, and said nanolipidic particles retain a concentration of said non-aqueous solvent from about 0.5% to 14%, with a passenger molecule encapsulated therein.
15. The NLP assembly population of claim 14 , wherein said passenger-loaded nanolipidic particles (NLP) have a mean size of about 1 nm to 20 nm.
16. The NLP assembly population of claim 14 , wherein said non-aqueous solvent is ethanol.
17. The NLP assembly population of claim 14 , wherein said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
18. The NLP assembly population of claim 14 , wherein said non-aqueous solvent is ethanol and said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
19. The NLP assembly population of claim 14 , wherein the mean size of said assembly is from about 80 nm to about 110 nm.
20. The NLP assembly population of claim 14 , wherein the mean size of said assembly is from about 110 nm to about 140 nm.
21. The NLP assembly population of claim 14 , wherein the mean size of said assembly is from about 150 nm to about 200 nm.
22. The NLP assembly population of claim 14 , wherein said NLP assembly populations are for oral consumption.
23. The NLP assembly population of claim 18 , wherein said NLP assembly populations are for oral consumption.
24. The NLP assembly population of claim 14 , wherein said NLP assembly populations are for topical application.
25. The NLP assembly population of claim 18 , wherein said NLP assembly populations are for topical application.
26. An NLP (Nanolipidic Particle) assembly population comprising:
one or more nanolipidic particles (NLPs) loaded with one or more passenger molecule, said nanolipidic particles formed from a hydrous monophasic precursor solution having phospholipids, water and a non-aqueous solvent selected from the group consisting of ethanol, 1-propanol, and 2-propanol, said hydrous monophasic precursor solution being diluted by one or more dilution of non-aqueous solvent, and then diluted with an aqueous solution,
wherein NLP assembly populations having a mean size of about 30 nm to about 200 nm form upon said dilution with said aqueous solution, said nanolipidic particles in said assemblies retaining a concentration of said non-aqueous solvent from about 0.5% to 14%.
27. The NLP assembly population of claim 26 , wherein said nanolipidic particles (NLPs) have a mean size of about 1 nm to 20 nm.
28. The NLP assembly population of claim 26 , wherein said non-aqueous solvent is ethanol.
29. The NLP assembly population of claim 26 , wherein said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
30. The NLP assembly population of claim 26 , wherein said non-aqueous solvent is ethanol and said phospholipids are selected from the group consisting of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidylinositol (PI), and mixtures thereof.
31. The NLP assembly population of claim 26 , wherein one or more of said nanolipidic particles loaded with a first passenger molecule and one or more of said nanolipidic particles loaded with a second passenger molecule are combined prior to dilution with said aqueous solution.
32. The NLP assembly population of claim 26 , wherein the mean size of said assembly is from about 80 nm to about 110 nm.
33. The NLP assembly population of claim 26 , wherein the mean size of said assembly is from about 110 nm to about 140 nm.
34. The NLP assembly population of claim 26 , wherein the mean size of said assembly is from about 150 nm to about 200 nm.
35. The NLP assembly population of claim 26 , wherein said NLP assembly populations are for oral consumption.
36. The NLP assembly population of claim 30 , wherein said NLP assembly populations are for oral consumption.
37. The NLP assembly population of claim 26 , wherein said NLP assembly populations are for topical application.
38. The NLP assembly population of claim 30 , wherein said NLP assembly populations are for topical application.